Actively Recruiting
Genotype-Guided Therapy Using Targeted Agents Plus CHOP Chemotherapy Versus Standard CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma Patients
Led by Ruijin Hospital · Updated on 2024-01-08
264
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a genotype-guided treatment approach for patients newly diagnosed with peripheral T-cell lymphoma PTCL, a diverse disease with generally poor outcomes using current standard therapies. The study includes both Phase I and Phase II stages. Phase I is an open-label trial to confirm the recommended Phase 2 dose RP2D of oral targeted agents tailored to three genetic subtypes of PTCL. Phase II is a multicenter, randomized, open-label study comparing the efficacy and safety of these genotype-guided targeted agents combined with standard chemotherapy CHOP-X2 versus standard CHOP chemotherapy alone.
CONDITIONS
Brief Title
Genotype-guided Treatment in Newly Diagnosed PTCL
Research Team
W
Weili Zhao
P
Pengpeng Xu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
